Cost and effectiveness of brinzolamide versus dorzolamide in current practice: An analysis based on the UK-GPRD database

Journal of Medical Economics

Volumn 6, Issue 69-78, 2003, Pages 69-78

  Deschaseaux Voinet, Céline ^a   Lafuma, Antoine ^a   Berdeaux, Gilles ^b,c  

^a CEMKA EVAL   (France)

^b Alcon Research Ltd   (France)

^c Alcon Laboratories   (France)

Author keywords

Carbonic anhydrase inhibitors; Cost; Effectiveness; Glaucoma

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; EYE SURGERY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATIONAL HEALTH SERVICE; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0346119161     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200306069078     Document Type: Article

References (17)

1. Understanding Glaucoma. London: The Royal College of Ophthalmologists/International Glaucoma Association, PNIB, 2000.
2. Evans J, Rooney C, Ashwood F et al. Blindness and partial sight in England and Wales, April 1990 - March 1991 Health Trends 1996; 28: 5-12.
3. Quigley HA. Number of patients with glaucoma worldwide. British Journal of Ophthalmology 1996; 80: 389-393.
4. Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmacoeconomics 1995; 7: 484-489.
5. Kobelt G, Jonsson L, Gerdtham U et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Archives of Clinical and Experimental Ophthalmology 1998; 236: 811-821.
6. Jönsson B, Krieglstein G. Primary open-angle glaucoma-differences in international treatment patterns and costs. Oxford, Isis Medical Media Ltd; 1998
7. Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Annals of Ophthalmology 1987; 19: 327-328.
8. Recent development in primary open angle glaucoma and ocular hypertensions. The National Prescribing Centre MeReC Bulletin 2003; 13: 17.
9. Schwartz GF, Platt R. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. American Journal of Managed Care 2002; 8 (Suppl.): S278-280.
10. Rouland JF, Le Pen C, Gouveia Pinto C et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 2003; 21: 201-213.
11. Halpern MT, Sorensen S, Covert D et al. Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide. Journal of Medical Economics 2000; 3: 111-120.
12. http://www.gprd.com/
13. http://www.bnf.org/
14. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clinical Therapeutics 2000; 22: 1204-1212.
15. Seong GJ, Lee SC, Lee JH et al. Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 2001; 215: 188-191.
16. Anderson DR. The management of elevated intraocular pressure with normal optic discs and visual fields. Surveys of Ophthalmology, 1977; 21: 479-489
17. Reyes E, Izquierdo NJ, Blasini M. Adverse drugs reactions associated with glaucoma medications. Boletin de la Asociacion Medica de Puerto Rico 1997; 89: 51-55.